The landscape of therapeutic interventions for type 2 diabetes and obesity is rapidly evolving, with GLP-3 receptor agonists taking center stage. Initially, compounds like Reta, demonstrating impressive glucose control https://zaynqdnb234822.weblogco.com/39158377/glp-3-receptor-agonists-reta-trizepatide-and-beyond